 |
|
|
| |
NNRTI-resistant Mutants Are Suppressed by Doravirine at Clinically Relevant Concentrations
|
| |
| |
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
Meizhen Feng1; Nancy Sachs2; Min Xu2; Jay Grobler1; Wade Blair1; Daria J. Hazuda1; Michael D. Miller1; Ming-Tain Lai1
Department of 1Antiviral Research, 2In Vitro Pharmacology, Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA
CROI:Doravirine 100 mg QD vs Efavirenz +TDF/FTC in ART-NaÏve HIV+ Patients: Week 48 Results - (02/26/16)
|
| |
|
|
|
|
|
